Preclinical evaluation of high-resolution CT, 18F-FDG, and 18F-NaF PET imaging for longitudinal monitoring of atherosclerosis
Our results show that <sup>18</sup>F-NaF PET and <sup>18</sup>F-FDG PET are sensitive imaging modalities for the early detection of atherosclerotic lesions. However, both <sup>18</sup>F-NaF PET and high-resolution microCT prove to be effective methods for monitoring late-stage and progressive disease.
Authors
- Richard Taschereau (ORCID: https://orcid.org/0000-0002-1035-0421)
- Shili Xu (ORCID: https://orcid.org/0000-0002-4933-8673)
- Matthew D. Worssam (ORCID: https://orcid.org/0000-0003-4391-5377)
- Arion F. Chatziioannou
- Mikayla Tamboline (ORCID: https://orcid.org/0000-0002-3675-2904)
- Wenduo Gu (ORCID: https://orcid.org/0000-0002-3859-3150)
- Jeffrey Collins
- Oluwatayo Ikotun (ORCID: https://orcid.org/0000-0003-3156-8291)
- Paul P. Cheng (ORCID: https://orcid.org/0000-0003-3429-2702)
- John David (ORCID: https://orcid.org/0000-0002-1267-9597)
- William Jackson
- Simon Jackson
Institutions
- Amgen (United States) (US)
- University of California, Los Angeles (US)
- Cardiovascular Institute of the South (US)
- UCLA Health (US)
- Los Angeles Medical Center (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1007/s00259-025-07276-1
- Citations
- 3
- Primary Topic
- Cerebrovascular and Carotid Artery Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Amgen
- National Institutes of Health
- National Center for Advancing Translational Sciences
- David Geffen School of Medicine, University of California, Los Angeles
- Clinical and Translational Science Institute, University of California, Los Angeles